Abstract
As an important part of China's national economy, pharmaceutical enterprises have also been greatly impacted. The pharmaceutical industry has always been a sunrise industry. However, with the outbreak of COVID-19, listed pharmaceutical companies will have an impact. According to the development of the epidemic situation and market environment in 2020, the main epidemic period can be divided into three stages. This paper uses the analysis of variance to calculate the return on equity, net profit on total assets, and operating net profit of listed pharmaceutical companies in the past four years to confirm whether the emergence of COVID-19 has had a significant impact on listed pharmaceutical companies. According to the research conclusions, the corresponding theoretical basis was provided for the listed pharmaceutical companies, so that they listed pharmaceutical companies could better serve the people during the epidemic. It was found that the outbreak of the epidemic did not have a great impact on listed pharmaceutical enterprises.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
